Studies for Individuals with Treatment-Resistant Depression

Tianeptine for Treatment-Resistant Depression

The purpose of this 8-week study is to evaluate the effectiveness of a medication called tianeptine for treating depression in people whose symptoms have not responded to two prior antidepressant treatments. Tianeptine is an investigational drug. This means that it has not been approved for use by the United States Food and Drug Administration (FDA), the branch of the federal government that approves new drugs, but it has been approved by the European Regulatory Agency and has been used to treat depression in Europe, Asia, and South America since the 1980s. Tianeptine is a different type of antidepressant than those currently approved in the United States in that it has a different mechanism of action than typical antidepressants. Tianeptine is an opioid agonist. This means that it binds and works via the mu opioid receptor. Currently approved antidepressants act on other systems of the brain that affect serotonin, norepinephrine and dopamine. Individuals with a history of substance use problems are not eligible as Tianeptine treatment is not recommended for those with substance use issues. Part of the study’s purpose is to investigate whether tianeptine may be particularly helpful for depressed individuals with a heightened experience of physical and emotional pain.

This study is recruiting individuals with depression who have had little or no success with at least two trials of antidepressant treatment in their current depressive episode. The study involves taking Tianeptine for 8 weeks and completing two MRI scans.

  • Ages 21-50
  • Individuals with treatment-resistant depression
  • At least 2 trials of antidepressant treatment with no or only partial remission
  • Free treatment with Tianeptine for 8 weeks
  • Compensation: up to $990.00

Optimizing Outcomes for Treatment Resistant Depression in Older Adults (OPTIMUM)

The purpose of this research study is to find out which antidepressants work best in individuals over the age of 60 years who have not responded or only partially responded to 2 or more prior antidepressant medications.

This study is recruiting individuals with depression who have had little or no success with at least two trials of antidepressant treatment in their current depressive episode. The study involves MRI scans and regular study visits – length of treatment is dependent on depressive symptoms.

  • Ages 60+ years
  • Individuals with treatment-resistant depression
  • At least 2 trials of antidepressant treatment with no or partial response
  • Two Step Randomized treatment
    • Step 1: switch to or add on Bupropion or add on Aripiprazole to current antidepressant medication.
    • Step 2: Add Lithium to current medication or switch to Nortriptyline
  • No placebo in this study
  • Available in English and Spanish
  • Up to two years of treatment
  • Up to $300 compensation

 

For more information, please call our research staff at (646) 774-8677 or fill out this form.

Para servicio en Español, llame a Esteban Ceballos al (646) 774-8670.